IDIBELL on the media
Kickoff to the XarSMART initiative, which aims to promote the transfer of medical technology in Catalonia
This is a proposal coordinated by IDIBELL and financed by AGAUR in which 13 other institutions participate. XarSMART will offer projects access to experts in regulatory, eHealth, data science and precision medicine.
A bioinformatics program will accelerate the diagnosis of hereditary cancer
Bioinformaticians from the Bellvitge Biomedical Research Institute (IDIBELL) and geneticists from the Molecular Diagnostic Laboratory of the Catalan Institute of Oncology (ICO) joined forces to develop a program that facilitates genetic variants classification, as it collects and combines the available information to offer a first classification of the variants.
Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients
It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.
Bellvitge Hospital and IDIBELL successfully test a new method to compare two multiple sclerosis treatments
The study compares the use of two drugs through what they have called a natural experiment, which opens the doors to a new research methodology to compare highly effective treatments, minimizing possible biases in the analysis of the different groups.
VacunAcció once again challenges students to get vaccinated against misinformation
This course, the educational project has been implemented in a group of Baccalaureate from the Escola Pia of Igualada
Consumption of processed foods increases the risk of cancer
This is the largest and most complete study carried out on the subject, it has included more than 450,000 people from 9 European countries and has analyzed the relationship of diet with 25 different types of cancer. The work concludes that replacing 10% of the intake of processed products with others that are not reduces the risk of suffering any type of cancer.
IDIBELL’s technology, licensed to LoopDx, starts a crowdequity campaign
Between 2018 and 2019, the IDIBELL and Bellvitge University Hospital researcher Joan Sabater, in collaboration with the start-up LoopDx, developed SeptiLoop, a rapid sepsis diagnostic kit. The result of this project was patented and licensed to the company itself.
A grant from the “la Caixa” Foundation allows Albert Antolín to set up his research at IDIBELL
Yesterday the award ceremony of the “la Caixa” Foundation scholarships was held. Dr. Albert Antolín, principal investigator of IDIBELL and ICO, received a Junior Leader grant to develop new strategies based on Big Data and artificial intelligence for the design of drugs against cancer that prevent drug resistance.
IDIBELL joins Brain Week with two scientific dissemination proposals
The play Abans que arribi l’alemany, about Alzheimer’s, and a flash talks session about Parkinson’s, bring neurodegenerative diseases closer to the public.
Presentation of the new cell sorter of the flow cytometry platform
The Flow Cytometry Platform of the IDIBELL Scientific-Technical Services incorporated new high-performance equipment. It is the Beckman Coulter CytoFLEX SRT Benchtop Cell Separator. The arrival of this state-of-the-art equipment covers the need to renew the cell separation service and makes new and current technological improvements available to researchers. CytoFLEX SRT can meet the requirements for […]